Calviri is a technology company.
Calviri has raised $2.0M across 1 funding round.
Calviri has raised $2.0M in total across 1 funding round.
Calviri has raised $2.0M in total across 1 funding round.
Calviri's investors include Golden Seeds.
Calviri is a biotechnology company founded in 2015 and headquartered in Phoenix, Arizona, dedicated to ending cancer through early-detection diagnostic tests and therapeutic/preventative vaccines for both humans and dogs.[1][2][4] It develops multi-cancer diagnostic products like StageOne Plus for canines, which detects five common cancers at stage 1 with high sensitivity, alongside human-focused tests for breast cancer detection and recurrence monitoring, and premade vaccines targeting shared tumor neoantigens (REDNs) derived from mRNA.[1][2][4][5] Serving pet owners, veterinarians, and global healthcare markets, Calviri addresses cancer as the leading cause of death in dogs (affecting 45% of those over 10) and second-leading in humans by enabling accessible, scalable early intervention; it has raised $19.66M, with the latest round in 2025, and maintains ongoing canine trials showing safety and efficacy.[1][2][4]
The company's growth momentum includes milestones like completing an 800+ dog VACCS preventative vaccine trial over five years, publishing stage 1 diagnostic results, validating manufacturing for diagnostic chips, and building the largest bank of stage 1 tumor blood samples from pets, positioning it for human transitions and spinouts.[2][4]
Calviri emerged as a spinout from the Arizona State University Biodesign Institute, founded in 2015 by Dr. Stephen Johnston, who shifted focus from DNA to RNA-level analysis after discovering shared "foreignness" in tumors via frameshift neoantigens—unique protein fragments tumors produce to survive, exploitable by the immune system like an infection.[3][4] Johnston's idea stemmed from recognizing clinical similarities between canine and human cancers, leveraging large-scale veterinary trials (e.g., hundreds of dogs in preventative vaccine studies) to generate data for human applications, as dog diagnostics and vaccines fund human versions.[2][3]
Early traction built through proprietary platforms: creating an mRNA-derived neoantigen database, functional screening chips, and pre-clinical validations by 2017-2020, followed by pivotal 2021-2025 milestones like the VACCS trial (showing safety/efficacy), diagnostic publications, and stage 1 HSA therapeutic vaccine initiation.[2][4] Based at Phoenix Bioscience Core, Calviri humanizes biotech by partnering pet owners with innovation, recently earning Bioscience Company of the Year.[1]
Calviri's edge lies in its neoantigen-microchip platform targeting shared RNA-derived frameshift neoantigens (REDNs), enabling off-the-shelf, premade vaccines and diagnostics unlike personalized therapies requiring custom discovery/preparation.[2][3][5]
Calviri rides the cancer vaccine and liquid biopsy wave, amplified by mRNA tech successes (e.g., COVID vaccines) and pet-human translational models, where canine trials de-risk human development amid rising demand for early detection amid 6M annual dog diagnoses.[2][3][5] Timing aligns with bioscience hubs like Arizona's ecosystem (AZBio, Phoenix Bioscience Core), where manufacturing scale-up meets global needs—cancer's canine prevalence mirrors human trends, but dog therapies lag, creating a $multi-billion veterinary-human bridge.[1][3]
Market forces favor it: validated safety from long-term trials, neoantigen focus exploits tumors' "Achilles' heel," and data-driven spinouts influence ecosystems by licensing diagnostics/vaccines, fostering AZ life sciences growth and global access.[2][4] It shapes biotech by proving pet models accelerate human oncology, potentially disrupting expensive personalized immunotherapies.[3][5]
Calviri is poised to launch canine StageOne Plus commercially, using revenues/data for human breast cancer diagnostics and vaccines, with ongoing HSA trials and spinouts expanding pipelines.[2][4] Trends like AI-neoantigen screening, ultrasound-drug synergies, and vet-human parallels will accelerate it, evolving influence from AZ innovator to global leader via partnerships/licensing.[1][2][3]
As cancer persists as a top killer, Calviri's pet-to-human model—rooted in Johnston's RNA insight—could make "ending cancer" feasible, transforming diagnostics into preventative reality.[5]
Calviri has raised $2.0M across 1 funding round. Most recently, it raised $2.0M Seed in April 2020.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Apr 1, 2020 | $2.0M Seed | Golden Seeds |